
CLAIMS

1. A compound of formula (I):



(I)


wherein:

Ring A is a 5 membered heteroaryl ring containing 2 heteroatoms independently selected from N and O;


Ring B is a 5 membered heteroaryl ring containing 2 or 3 heteroatoms each independently selected from N, S and O, wherein at least one of said heteroatoms is N or ring B is a 6 membered heteroaryl containing 1 or 2 heteroatoms selected from N;


R^1 is hydrogen or halogen;

R^2 is selected from the group consisting of:




,





and



wherein

R^{2a} is H, $(C_1\text{-}C_4)$alkyl or phenyl, wherein said $(C_1\text{-}C_4)$alkyl is optionally substituted with halogen, $(C_3\text{-}C_6)$cycloalkyl, phenyl, -O-$(C_1\text{-}C_4)$alkyl or -S-$(C_1\text{-}C_4)$alkyl;

R^{2b} is H, $(C_1\text{-}C_4)$alkyl or R^{2b} taken together with R^{2a} forms a $(C_3\text{-}C_6)$cycloalkyl ring;

R^{2c} is $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl or benzyl;

R^{2d} is $(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_6)$cycloalkyl, adamantyl, a 5 or 6 membered heteroaryl wherein said heteroaryl contains 1 or 2 heteroatoms independently selected from N and O, or

phenyl; wherein said phenyl is optionally substituted with 1 or 2 substituents independently selected from (C_1-C_4)alkyl, halo-(C_1-C_4)alkyl and nitrile;



R^{2e} is H, (C_1-C_4)alkyl or (C_3-C_6)cycloalkyl ring;



R^{2f} is H, (C_1-C_4)alkyl or (C_3-C_6)cycloalkyl ring optionally substituted with (C_1-C_4)alkyl or R^{2e} taken together with R^{2f} forms a (C_3-C_6)cycloalkyl ring;

R^{2g} is H, (C_1-C_4)alkyl, a fused moiety selected from benzo[d][1,3]dioxole and indolin-2-one, where said fused moiety is optionally substituted with halogen or (C_1-C_4)alkyl, (C_3-C_6)heterocycloalkyl containing 1 or 2 heteroatoms selected from N and O, -(C_0-C_2)alkyl-phenyl wherein said phenyl is optionally substituted 1 or 2 groups independently selected from halogen and (C_1-C_4)alkyl;

R^3 is H, (C_1-C_5)alkyl or a 4 to 6 membered saturated heterocycle containing O; wherein said (C_1-C_5)alkyl is optionally substituted with 1 to 3 groups independently selected from hydroxyl, (C_1-C_5)alkoxy, halogen, diethyl phosphate, -C(O)O(C_1-C_4)alkyl, NH-benzyl, O-benzyl, benzo[d][1,3]dioxole, isoindolinyl, -O-(C_2-C_4)alkyl-O-(C_1-C_4)alkyl, and a 4 to 6 membered saturated heterocycle containing 1 or 2 heteroatoms selected from N and O wherein said heterocycle is optionally substituted with 1 or 2 groups selected from (C_1-C_4)alkyl, and -C(O)NH(CHR^5)C(O)O-(C_1-C_4)alkyl;

R^4 is selected from the group consisting of:


,

,


and

;

where

R^{4a} is H, (C_1-C_4)alkyl or phenyl, wherein said (C_1-C_4)alkyl is optionally substituted with 1 to 3 halogens, (C_3-C_6)cycloalkyl, phenyl, -O-(C_1-C_4)alkyl or -S-(C_1-C_4)alkyl;

R^{4b} is H or (C_1-C_4)alkyl or R^{4b} taken together with R^{4a} to form a (C_3-C_6)cycloalkyl ring;

R^{4c} is (C_1-C_4)alkyl, (C_2-C_4)alkenyl or benzyl;

R^{4e} is H, (C_1-C_4)alkyl, (C_1-C_4)alkoxy or (C_3-C_6)cycloalkyl ring;

R^{4f} is H, (C_1-C_4)alkyl or (C_3-C_6)cycloalkyl ring optionally substituted with nitrile or (C_1-C_4)akyl or R^{4e} taken together with R^{4f} to form a (C_3-C_6)cycloalkyl ring;

R^{4g} is H, (C_1-C_4)alkyl, a fused moiety selected from benzo[d][1,3]dioxole and indolin-2-one, where said fused moiety is optionally substituted with halogen or (C_1-C_4)alkyl, (C_3-C_6)heterocycloalkyl containing 1 or 2 heteroatoms selected from N and O, -(C_0-C_2)alkyl-


phenyl wherein said phenyl is optionally substituted with 1 or 2 halogens;

R^{4h} is (C_1-C_4)alkyl, (C_3-C_6)cycloalkyl optionally substituted with 1 or 2 halogens, adamantyl, 5 or 6 membered heteroaryl wherein said heteroaryl contains 1 or 2 heteroatoms independently selected from N and O, phenyl; wherein said phenyl is optionally substituted with 1 or 2 substituents independently selected from (C_1-C_4)alkyl, (C_1-C_5)alkoxy, halo-(C_1-C_4)alkyl, halo-(C_1-C_4)alkoxy and nitrile;

R^{4i} is H or R^{4i} taken together with R^{4h} forms a (C_3-C_6)heterocycloalkyl ring optionally substituted with 1 or 2 substituents independently selected from (C_1-C_4)alkyl, (C_1-C_4)alkoxy and -C(O)O(C_1-C_4)alkyl; and









R^5 is H or (C_1-C_4)alkyl, wherein said (C_1-C_4)alkyl is optionally substituted with (C_3-C_6)cycloalkyl, phenyl, -O-(C_1-C_4)alkyl or -S-(C_1-C_4)alkyl;
or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.

2. The compound of claim 1 of formula (Ia):




(Ia)

wherein:
Ring B is selected from the group consisting of the following wherein * indicates the point of attachment:


,

,

,

,

,

,

and

;

or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.




3. The compound of claim 1 or 2 of formula (Ia):








(Ia)

wherein:




Ring B is selected from the group consisting of the following wherein * indicates the point of attachment:





, 
, 
,





, 
, 
,



and 
;

R^3 is selected from the group consisting of the following wherein * indicates the point of attachment: *H,


, 
, 
, 
,


, 
, 
, 
,



, 
, 
, 
,


and 
;

or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.

4. The compound according to any of the preceding claims wherein:
R^1 is hydrogen;
or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.


5. The compound of claim 1 or 2 of formula (IIa):



(IIa)

or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.


6. The compound of claim 1 or 2 of formula (IIb):



(IIb)

or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.


7. The compound of claim 1 or 2 of formula (IIc):



(IIc)

or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.

8. The compound of claim 1 or 2 of formula (IId):




(IId)

or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.


9. The compound of any one of the preceding claims, wherein:

R^1 is H;

R^2 is selected from the group consisting of:



and



;

where

R^{2a} is H, $(C_1\text{-}C_4)$alkyl or phenyl, wherein said $(C_1\text{-}C_4)$alkyl is optionally substituted with halogen, $(C_3\text{-}C_6)$cycloalkyl, phenyl, -O-$(C_1\text{-}C_4)$alkyl or -S-$(C_1\text{-}C_4)$alkyl;

R^{2b} is H, $(C_1\text{-}C_4)$alkyl or R^{2b} taken together with R^{2a} forms a $(C_3\text{-}C_6)$cycloalkyl ring;

R^{2c} is $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl or benzyl;


R^{2e} is H, $(C_1\text{-}C_4)$alkyl or $(C_3\text{-}C_6)$cycloalkyl ring;

R^{2f} is H, $(C_1\text{-}C_4)$alkyl or $(C_3\text{-}C_6)$cycloalkyl ring optionally substituted with $(C_1\text{-}C_4)$alkyl or R^{2e} taken together with R^{2f} forms a $(C_3\text{-}C_6)$cycloalkyl ring;


R^{2g} is H, $(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_6)$heterocycloalkyl containing 1 or 2 heteroatoms selected from N and O, -$(C_0\text{-}C_2)$alkyl-phenyl wherein said phenyl is optionally substituted 1 or 2 groups independently selected from halogen and $(C_1\text{-}C_4)$alkyl;

R^3 is H;


R^4 is selected from the group consisting of:



,



and



;

where

R^{4a} is H, $(C_1\text{-}C_4)$alkyl, phenyl, wherein said $(C_1\text{-}C_4)$alkyl is optionally substituted with 1 to 3 halogens, $(C_3\text{-}C_6)$cycloalkyl, phenyl, -O-$(C_1\text{-}C_4)$alkyl or -S-$(C_1\text{-}C_4)$alkyl;

R^{4b} is H or $(C_1\text{-}C_4)$alkyl or R^{4b} taken together with R^{4a} to form a $(C_3\text{-}C_6)$cycloalkyl ring;

R^{4c} is $(C_1\text{-}C_4)$alkyl, $(C_2\text{-}C_4)$alkenyl and benzyl;

R^{4e} is H, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy or $(C_3\text{-}C_6)$cycloalkyl ring;

R^{4f} is H, $(C_1\text{-}C_4)$alkyl or $(C_3\text{-}C_6)$cycloalkyl ring optionally substituted with nitrile or $(C_1\text{-}C_4)$akyl or R^{4e} taken together with R^{4f} to form a $(C_3\text{-}C_6)$cycloalkyl ring;

R^{4g} is H, $(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_6)$heterocycloalkyl containing 1 or 2 heteroatoms selected from N and O, -$(C_0\text{-}C_2)$alkyl-phenyl wherein said phenyl is optionally substituted with 1 or 2 halogens;


R^{4h} is $(C_1\text{-}C_4)$alkyl, $(C_3\text{-}C_6)$cycloalkyl optionally substituted with 1 or 2 halogens, adamantyl, a 5 or 6 membered heteroaryl wherein said heteroaryl contains 1 or 2 heteroatoms independently selected from N and O, or phenyl; wherein said phenyl is optionally substituted with 1 or 2 substituents independently selected from $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_5)$alkoxy, halo-$(C_1\text{-}C_4)$alkyl, halo-$(C_1\text{-}C_4)$alkoxy and nitrile; and












R^{4i} is H or R^{4i} taken together with R^{4h} to form a $(C_3\text{-}C_6)$heterocycloalkyl ring optionally substituted with 1 or 2 substituents independently selected from $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy and -C(O)O$(C_1\text{-}C_4)$alkyl;

















or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.

10. The compound of claim 1 or 2 wherein:

R^2 is selected from the group consisting of:




,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

and

;

or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.


11. The compound of claim 1 or 2 wherein:

R^4 is selected from the group consisting of:




or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.

12. The compound of claims 1, 2 or 5 of formula (IIa):




(IIa)

wherein R^2 is selected from the group consisting of:




R^4 is selected from the group consisting of:




or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.

13. The compound according to claims 1, 2 or 6 of formula (IIb):




(IIb)

wherein R^2 is selected from the group consisting of:




R^4 is selected from the group consisting of:




or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.

14. The compound according to claims 1, 2 or 7 of formula (IIc):




(IIc)

wherein R^2 is selected from the group consisting of:




R^4 is selected from the group consisting of:




or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.

15. The compound according to claims 1, 2 or 8 of formula (IId):




(IId)

wherein R^2 is selected from the group consisting of:




R^4 is selected from the group consisting of:











or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.

16. The compound according to claims 1, 2, 12, 13, 14 or 15 wherein R^2 is selected from the group consisting of:



R^4 is selected from the group consisting of:


,

,

,

,

,

,

and

;

or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.

17. The compound of claim 1 selected from the group consisting of:

methyl (2-(3-(5-((dicyclopropylmethyl)carbamoyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

N-cyclopentyl-2-(3-(5-(cyclopentylcarbamoyl)-1-(3-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide;

2-(3-(2-(((S)-1-cyclopropylethyl)carbamoyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-imidazol-4-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(1-(2-hydroxyethyl)-5-(pentan-3-ylcarbamoyl)-1H-1,2,4-triazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

(S)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (1-(2-morpholinoethyl)-3-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-5-carbonyl)-L-valinate;

ethyl (2-(3-(5-((dicyclopropylmethyl)carbamoyl)-1-(2-hydroxyethyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

methyl (2-(3-(5-((dicyclopropylmethyl)carbamoyl)-1-(2-hydroxyethyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

N-(2-methylpentan-3-yl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(5-(pentan-3-ylcarbamoyl)-1-(2-(piperidin-1-yl)ethyl)-1H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

methyl (2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(1-(2-methoxyethyl)-5-(pentan-3-ylcarbamoyl)-1H-1,2,4-triazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (2-(3-(5-((dicyclopropylmethyl)carbamoyl)-1-(3-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(1-(2-(benzylamino)ethyl)-5-(pentan-3-ylcarbamoyl)-1H-1,2,4-triazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-leucinate;

N-(pentan-3-yl)-2-(3-(3-((1-(tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

tert-butyl (2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

(S)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-1-(oxetan-3-yl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (2-(3-(5-((dicyclopropylmethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(3-((1-cyanopropyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(3-((1-cyclopropyl-2-methoxyethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

N-((S)-1-cyclopropylethyl)-2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(3-hydroxypropyl)-1H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

2-(3-(1-(2-(2-methoxyethoxy)ethyl)-5-(pentan-3-ylcarbamoyl)-1H-1,2,4-triazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

(S)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-1-(2-isopropoxyethyl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

methyl (2-(3-(5-((dicyclopropylmethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

methyl (2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

benzyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-valinate;

ethyl (1-(2-(benzyloxy)ethyl)-3-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-5-carbonyl)-L-valinate;

(S)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-1-methyl-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

(S)-2-(3-(2-((1-cyclopropylethyl)carbamoyl)-1H-imidazol-4-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (1-(2-((diethoxyphosphoryl)oxy)ethyl)-3-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-5-carbonyl)-L-valinate;

(R)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-1-(2-hydroxyethyl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(2-hydroxyethyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

methyl (2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(3-((cyclobutylmethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

tert-butyl O-(tert-butyl)-N-(5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-serinate;

2-(3-(3-([1,1'-bi(cyclopropan)]-1-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

methyl (3-(3-(5-((dicyclopropylmethyl)carbamoyl)oxazol-2-yl)phenyl)-1H-1,2,4-triazole-5-carbonyl)-L-valinate;

N-(pentan-3-yl)-2-(3-(4-(pentan-3-ylcarbamoyl)pyridin-2-yl)phenyl)oxazole-5-carboxamide;

N-(dicyclopropylmethyl)-2-(3-(5-((dicyclopropylmethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

N-((R)-1-cyclopropylethyl)-2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide

tert-butyl (2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

ethyl (2-(3-(5-((1,1,1-trifluorobutan-2-yl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(3-((2-cyclopropylpropan-2-yl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(3-((1-cyanopropyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (2-(3-(5-((1-cyclopropyl-2,2,2-trifluoroethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

ethyl (3-(3-(5-((dicyclopropylmethyl)carbamoyl)oxazol-2-yl)phenyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-5-carbonyl)-L-valinate;

2-(3-(3-((cyclopropyl(tetrahydrofuran-2-yl)methyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

tert-butyl O-(tert-butyl)-N-(2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-serinate;

2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)-N-(dicyclopropylmethyl)oxazole-5-carboxamide;

methyl (2-(3-(5-((dicyclopropylmethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

ethyl (2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

N-(pentan-3-yl)-2-(3-(5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide;

ethyl (2-(3-(3-(((S)-1-ethoxy-3-methyl-1-oxobutan-2-yl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(1-(2-hydroxyethyl)-5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)-N-(2-methyl pentan-3-yl)oxazole-5-carboxamide;

N-(tert-butyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

ethyl (2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-methioninate;

tert-butyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-leucylglycinate;

ethyl (1-(2-hydroxyethyl)-3-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-5-carbonyl)-L-valinate;

(R)-2-(3-(3-((3-methylbutan-2-yl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

methyl (2-(3-(5-(((S)-1-methoxy-3-methyl-1-oxobutan-2-yl)carbamoyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

N-(pentan-3-yl)-2-(3-(3-((2-phenylpropan-2-yl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

2-(3-(3-((1-cyanopropyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(3-(((R)-1-((2R,5R)-5-methyltetrahydrofuran-2-yl)propyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

N-((R)-1-cyclopropylethyl)-2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(2-hydroxyethyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide;

ethyl (2-(3-(1-(2-(((S)-1-ethoxy-3-methyl-1-oxobutan-2-yl)amino)-2-oxoethyl)-5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(1-(2-hydroxyethyl)-5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)-N-(p-tolyl)oxazole-5-carboxamide;

(S)-N-(1-cyclopropylethyl)-2-(3-(1-(2-hydroxyethyl)-5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide;

ethyl (R)-2-(5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carboxamido)-2-phenylacetate;

2-(3-(1-(2-(benzyloxy)ethyl)-5-(pentan-3-ylcarbamoyl)-1H-1,2,4-triazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

(S)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

methyl (2-(3-(5-((dicyclopropylmethyl)carbamoyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

ethyl (2-(3-(1-(4-(tert-butoxy)-4-oxobutyl)-5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

diethyl 2,2'-((2,2'-(1,3-phenylene)bis(oxazole-2,5-diyl-5-carbonyl))bis(azanediyl))(2S,2'S)-bis(3-methylbutanoate);

2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(2-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(2,3-dihydroxypropyl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(1-(2-(isoindolin-2-yl)ethyl)-5-(pentan-3-ylcarbamoyl)-1H-1,2,4-triazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

methyl (S)-3-cyclohexyl-2-(2-(3-(3-((dicyclopropylmethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamido)propanoate;

N-((S)-1-cyclopropylethyl)-2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(2-hydroxyethyl)-1H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(3-(((1S)-1-(tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(3-(((S)-1-((S)-tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(3-(((S)-1-((R)-tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide

ethyl (2-(3-(1-(3-(tert-butoxy)-3-oxopropyl)-5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

ethyl (2-(3-(1-(3-(tert-butoxy)-3-oxopropyl)-5-(((S)-1-cyclopropylethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

N-((R)-1-cyclopropylethyl)-2-(3-(5-(((R)-1-cyclopropylethyl)carbamoyl)-1-(2-hydroxyethyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide;

ethyl (2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

(S)-N-(pentan-3-yl)-2-(3-(3-((1-phenylethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

methyl (S)-2-(2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamido)-2-phenylacetate;

tert-butyl (2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-leucylglycinate;

ethyl (2-(3-(5-((dicyclopropylmethyl)carbamoyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2,2'-(2-methyl-1,3-phenylene)bis(N-(pentan-3-yl)oxazole-5-carboxamide);

methyl (2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carbonyl)-L-leucinate;

ethyl (2-(3-(5-((1-cyclopropyl-2,2-difluoroethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(3-((2-cyclopropyl-1,1,1-trifluoropropan-2-yl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

methyl (2-(3-(3-(((R)-1-cyclopropylethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(3-((2-methyl-4-phenylbutan-2-yl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (2-(3-(5-((1-cyclopropyl-2,2,2-trifluoroethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

N-(pentan-3-yl)-2-(3-(5-(pentan-3-ylcarbamoyl)-1-(2-(piperidin-1-yl)ethyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide;

2,2'-(1,3-phenylene)bis(N-(pentan-3-yl)oxazole-5-carboxamide);

2-(3-(3-((1-methoxy-3-methylbutan-2-yl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (5-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)oxazol-2-yl)phenyl)-4H-1,2,4-triazole-3-carbonyl)-L-valinate;

ethyl (2-(3-(3-((1-cyclopropyl-2,2,2-trifluoroethyl)carbamoyl)-1H-1,2,4-triazol-5-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(3-((2-isopropoxyethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(3-(cyclohexylcarbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(5-(pentan-3-ylcarbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

ethyl 4-(5-(pentan-3-ylcarbamoyl)-3-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-1,2,4-triazol-1-yl)butanoate;

2-(3-(3-((1-cyclobutylethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-valinate;

N-(4-fluorobenzyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

2-(3-(3-((2-methylpentan-3-yl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

(R)-N-(1-cyclopropylethyl)-2-(3-(5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(3-(((1S)-1-(tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(3-(((S)-1-((S)-tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(3-(((S)-1-((R)-tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

methyl (S)-2-(2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamido)-3,3-dimethylbutanoate;

(S)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)-N-(dicyclopropylmethyl)oxazole-5-carboxamide;

methyl (2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

(S)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(1-phenylethyl)oxazole-5-carboxamide;

isopropyl (2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

(S)-2-(3-(3-((1-methoxypropan-2-yl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

methyl (2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-leucinate;

(S)-N-(1-cyclopropylethyl)-2-(3-(5-((dicyclopropylmethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

N-(1-cyclopropylethyl)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-1-(2-hydroxyethyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide;

ethyl (2-(3-(1-(2-morpholinoethyl)-5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

(S)-2-(3-(3-((1-cyclopropylethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

(S)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)-N-(dicyclopropylmethyl)oxazole-5-carboxamide;

methyl 1-(5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)pyrrolidine-3-carboxylate;

N-(heptan-4-yl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

2-(3-(3-(heptan-4-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(3-((cyclopropyl(tetrahydrofuran-2-yl)methyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

N-((S)-1-cyclopropylethyl)-2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(2-hydroxyethyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide;

methyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-valinate;

(S)-2-(3-(4-((1-cyclopropylethyl)carbamoyl)thiazol-2-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(5-((cyclohexylmethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

N-(2-methyl-4-phenylbutan-2-yl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

ethyl 6-(5-(pentan-3-ylcarbamoyl)-3-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-1,2,4-triazol-1-yl)hexanoate;

(S)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-1-(2-hydroxyethyl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

(R)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)-N-(dicyclopropylmethyl)oxazole-5-carboxamide;

ethyl (2-(3-(5-(((R)-1-methoxy-3-methyl-1-oxobutan-2-yl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

methyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-leucinate;

2-(3-(3-(2-isopropylpyrrolidine-1-carbonyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (2-(3-(5-((dicyclopropylmethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(3-(trifluoromethyl)phenyl)oxazole-5-carboxamide;

ethyl (2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-leucinate;

N-(3-cyanophenyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide

2-(3-(1-(2-(benzyloxy)ethyl)-5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (2-(3-(5-((1-cyclopropyl-2,2,2-trifluoroethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

methyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-alaninate;

2-(3-(1-(2-hydroxyethyl)-5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (2-(3-(1-(4-(tert-butoxy)-4-oxobutyl)-5-(((S)-1-cyclopropylethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

(S)-N-(adamantan-1-yl)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

ethyl (R)-2-(2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamido)-2-phenylacetate;

methyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)phenylalaninate;

2-(3-(3-(tert-butylcarbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazol-3-yl)phenyl)-N-(dicyclopropylmethyl)oxazole-5-carboxamide;

(S)-N-(1-cyclohexylethyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

methyl N-(2-(3-(3-(((S)-1-cyclopropylethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-S-methyl-D-cysteinate;

2-(3-(4-(2-methoxyethyl)-5-(pentan-3-ylcarbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

N-cyclopentyl-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

methyl (5-(3-(5-(((S)-1-ethoxy-3-methyl-1-oxobutan-2-yl)carbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-leucinate;

(R)-2-(3-(3-((1-cyclohexylethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

N-(3,5-dimethylphenyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

(S)-2-(3-(4-((1-cyclopropylethyl)carbamoyl)-1H-imidazol-2-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl 3-methyl-1-(5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)pyrrolidine-3-carboxylate;

ethyl (2-(3-(3-(((R)-1-cyclopropylethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

tert-butyl (S)-2-(2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamido)-2-phenylacetate;

ethyl (2-(3-(1-(2-hydroxyethyl)-5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

2-(3-(3-((4-fluorobenzyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl 2-(5-(pentan-3-ylcarbamoyl)-3-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-1,2,4-triazol-1-yl)acetate;

2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)-N-((S)-3-methylbutan-2-yl)oxazole-5-carboxamide;

methyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-D-methioninate;

N-((R)-1-cyclopropylethyl)-2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

(S)-N-(1-cyclopropylethyl)-2-(3-(5-((4,4-difluorocyclohexyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

ethyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-phenylalaninate;

ethyl (2-(3-(3-(((S)-1-cyclopropylethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

N-(pentan-3-yl)-2-(3-(3-(((1S)-1-(tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(3-(((S)-1-((S)-tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(3-(((S)-1-((R)-tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

diallyl 2,2'-((2,2'-(1,3-phenylene)bis(oxazole-2,5-diyl-5-carbonyl))bis(azanediyl))(2S,2'S)-bis(3-methylbutanoate);

2-(3-(3-((2-(tert-butylthio)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

(R)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)-N-((tetrahydro-2H-pyran-2-yl)methyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(4-(pentan-3-ylcarbamoyl)-1H-imidazol-2-yl)phenyl)oxazole-5-carboxamide;

N-((R)-1-cyclopropylethyl)-2-(3-(3-(((R)-1-cyclopropylethyl)carbamoyl)-1H-1,2,4-triazol-5-yl)phenyl)oxazole-5-carboxamide;

isopropyl (2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)glycinate;

methyl (S)-3-cyclohexyl-2-(2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamido)propanoate;

methyl (2-(3-(3-(((S)-1-methoxy-4-methyl-1-oxopentan-2-yl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-leucinate;

2-(3-(3-((2,6-difluorobenzyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(3-(4-methoxy-4-methylpiperidine-1-carbonyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

(S)-2-(3-(3-(sec-butylcarbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(3-((2-methoxy-2-methylpropyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

tert-butyl 2-methyl-2-(2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamido)propanoate;

methyl (2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

benzyl (2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-alaninate;

tert-butyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-valinate;

methyl (R)-2-(5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carboxamido)-2-phenylacetate;

(S)-N-(sec-butyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

2-(3-(3-((3-isopropoxyphenyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

N-((S)-1-cyclopropylethyl)-2-(3-(5-(((R)-1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

2-(3-(3-(cyclopentylcarbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

N-((S)-1-cyclopropylethyl)-2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide;

2-(3-(3-((cyclopropyl(tetrahydrofuran-2-yl)methyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

tert-butyl 2-(5-(pentan-3-ylcarbamoyl)-3-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-1,2,4-triazol-1-yl)acetate;

ethyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-alaninate;

2-(3-(3-(3,3-dimethylpiperidine-1-carbonyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

(S)-N-([1,1'-bi(cyclopropan)]-1-yl)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

benzyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-alaninate;

(S)-2-(3-(3-((1-cyclohexylethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

N-((1-methylcyclohexyl)methyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

(R)-N-(1-cyclohexylethyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

methyl (5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)-L-phenylalaninate;

tert-butyl 1-(5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carbonyl)pyrrolidine-3-carboxylate;

methyl (S)-1-(2-(3-(5-((1-cyclopropylethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamido)cyclobutane-1-carboxylate;

N-(2,6-difluorobenzyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

2-(3-(3-(((1-methylcyclopropyl)methyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (2-(3-(5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-D-valinate;

N-benzyl-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

methyl (2-(3-(3-(((S)-1-cyclopropylethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

(S)-2-(3-(3-((3,3-dimethylbutan-2-yl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

ethyl (2-(3-(1-(2-(tert-butoxy)-2-oxoethyl)-5-(pentan-3-ylcarbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

ethyl (2-(3-(5-((1,1,1-trifluoropropan-2-yl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carbonyl)-L-valinate;

(R)-N-(3-methylbutan-2-yl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

2-(3-(3-(((1-morpholinocyclohexyl)methyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

(R)-N-(pentan-3-yl)-2-(3-(3-((1-phenylethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(3-((3-(trifluoromethoxy)phenyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

2-(3-(3-(benzylcarbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)-N-(1-cyclopropylpropyl)oxazole-5-carboxamide;

ethyl (S)-3-cyclohexyl-2-(5-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-pyrazole-3-carboxamido)propanoate;

2-(3-(3-((cyclohexylmethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

N-(3-chlorophenyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

methyl (R)-2-(2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamido)-2-phenylacetate;

2,2'-(4-fluoro-1,3-phenylene)bis(N-(pentan-3-yl)oxazole-5-carboxamide);

N-(benzo[d][1,3]dioxol-5-ylmethyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

ethyl 2-methyl-2-(2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamido)propanoate;

tert-butyl 2-(5-(pentan-3-ylcarbamoyl)-3-(3-(5-(pentan-3-ylcarbamoyl)oxazol-2-yl)phenyl)-1H-1,2,4-triazol-1-yl)acetate;

N-((S)-1-cyclopropylethyl)-2-(3-(5-(((S)-1-cyclopropylethyl)carbamoyl)-4H-1,2,4-triazol-3-yl)phenyl)oxazole-5-carboxamide;

ethyl (S)-2-(2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamido)-2-phenylacetate;

N-(isoxazol-3-yl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

N-(1-cyclopropylethyl)-2-(3-(5-((1-cyclopropylethyl)carbamoyl)-1H-pyrazol-3-yl)phenyl)oxazole-5-carboxamide;

(S)-N-(1-cyclopropylethyl)-2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

N-(pentan-3-yl)-2-(3-(3-(piperidine-1-carbonyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide;

ethyl (2-(3-(3-(pentan-3-ylcarbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carbonyl)-L-phenylalaninate; and

2-(3-(3-((benzo[d][1,3]dioxol-5-ylmethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)-N-(pentan-3-yl)oxazole-5-carboxamide;

or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof.

18. A pharmaceutical composition comprising a compound of any one of the preceding claims or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof, and a pharmaceutically acceptable carrier, or diluent.

19. The pharmaceutical composition of claim 18, further comprising one or more additional pharmaceutical agent(s).

20. The pharmaceutical composition of claim 19, wherein the one or more additional pharmaceutical agent(s) is selected from a mucolytic agent(s), nebulized hypertonic saline, bronchodilator(s), an antibiotic(s), an anti-infective agent(s), a CFTR modulator(s), and an anti-inflammatory agent(s).

21. The pharmaceutical composition of claim 19, wherein the one or more additional pharmaceutical agent(s) is a CFTR modulator(s).

22. The pharmaceutical composition of claim 19, wherein the one or more additional pharmaceutical agent(s) is a CFTR corrector(s).

23. The pharmaceutical composition of claim 19, wherein the one or more additional pharmaceutical agent(s) is a CFTR potentiator(s).

24. The pharmaceutical composition of claim 19, wherein the one or more additional pharmaceutical agent(s) comprise a CFTR amplifier(s).

25. Use of a compound or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof of any one of claims 1 to 17 or the pharmaceutical composition of any one of claims 18 to 24 in the manufacture of a medicament ~~A method~~ for the treat~~ing~~ment of a disease associated with impaired mucociliary clearance in a subject. ~~comprising administering to the subject a compound or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof of any one of claims 1 to 17 or the pharmaceutical composition of any one of claims 18 to 24.~~

~~26.~~

~~The method of claim 25,~~ wherein the disease associated with impaired mucociliary clearance is selected from cystic fibrosis, asthma, bronchiectasis, COPD, and chronic bronchitis.

~~27.~~26. The ~~method~~ use of claim 2~~5~~6, wherein the disease associated with impaired mucociliary clearance is cystic fibrosis, or COPD.

~~28.~~27. The ~~method~~ use of claim 2~~5~~6, wherein the disease associated with impaired mucociliary clearance is cystic fibrosis.

~~29.~~28. The ~~method~~ use of claim 25, wherein ~~further comprising administering to the subject~~ one or more additional pharmaceutical agent(s) are to be administered to the subject, prior to, concurrent with, or subsequent to the ~~compound~~ medicament~~of any one of claims 1 to 17 or the pharmaceutical composition of any one of claims 18 to 24~~.

~~30.~~29. The ~~method~~ use of claim 2~~8~~9, wherein the one or more additional pharmaceutical agent(s) is selected from a mucolytic agent(s), nebulized hypertonic saline, bronchodilator(s), an antibiotic(s), an anti-infective agent(s), a CFTR modulator(s), and an anti-inflammatory agent(s).

~~31.~~30. The ~~method~~ use of claim 2~~8~~9, wherein the one or more additional pharmaceutical agent(s) is a CFTR modulator(s).

~~32.~~31. The ~~method~~ use of claim 2~~8~~9, wherein the one or more additional pharmaceutical agent(s) is a CFTR potentiator(s).

~~33.~~32. The ~~method~~ use of claim 2~~8~~9, wherein the one or more additional pharmaceutical agent(s) comprise a CFTR amplifier(s).

~~34.~~33. A monohydrate form of the free base of N-(pentan-3-yl)-2-(3-(3-(((S)-1-((S)-tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide wherein the monohydrate form has an X-ray powder diffraction pattern comprising a characteristic peak, in terms of 2θ, at about 24.6°.

~~35.~~34. The monohydrate form of claim 3~~3~~4, wherein the X-ray powder diffraction pattern further comprises one or more characteristic peaks, in terms of 2θ, selected from peaks at about 7.6°, about 12.0°, about 15.6°, about 16.6°, about 18.6°, about 18.9°, about 21.5°, and about 23.1°.

~~36.~~35. The monohydrate form of claim 3~~3~~4 having an X-ray powder diffraction pattern substantially as shown in Figure 1A.

~~37.~~36. The monohydrate form of claim 3~~3~~4 having a differential scanning calorimetry thermogram showing an onset of an endotherm at about 104.6°C.

~~38.~~37. The monohydrate form of claim 3~~3~~4 having a differential scanning calorimetry thermogram substantially as shown in figure 1B.

~~39.~~38. The monohydrate form of claim 3~~3~~4 having a differential scanning calorimetry thermogram substantially as shown in figure 1C.

~~40.~~39. A metastable hydrate form of the free base of N-(pentan-3-yl)-2-(3-(3-(((S)-1-((S)-tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide wherein the metastable hydrate form has an X-ray powder diffraction pattern comprising a characteristic peak, in terms of 2θ, at about 5.0°.

~~41.~~40. The metastable hydrate form of claim ~~40~~ 39 where in the X-ray powder diffraction pattern further comprises one or more characteristic peaks, in terms of 2θ, selected from peaks at about 15.1°, about 16.3°, about 18.9°, about 19.1°, and about 20.6°.

~~42.~~41. The metastable hydrate form of claim ~~40~~ 39 having an X-ray powder diffraction pattern substantially as shown in Figure 2A.

~~43.~~42. The metastable hydrate form of claim ~~40~~ 39 having a differential scanning calorimetry thermogram showing an onset of an endotherm at about 34.0°C and a second onset of an endotherm at 159.0°C.

~~44.~~43. The metastable hydrate form of claim ~~40~~ 39 having a differential scanning calorimetry thermogram substantially as shown in figure 2B.

~~45.~~44. An anhydrous form A of the free base of N-(pentan-3-yl)-2-(3-(3-(((S)-1-((S)-tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide wherein the monohydrate form has an X-ray powder diffraction pattern comprising a

characteristic peak, in terms of 2θ, at about 6.2°.

~~46.~~45. The anhydrous form A of claim ~~45~~44, wherein the X-ray powder diffraction pattern further comprises one or more characteristic peaks, in terms of 2θ, selected from peaks at about 13.5°, about 16.5°, about 18.5°, about 18.9°, about 20.4°, and about 24.8°.

~~47.~~46. The anhydrous form A of claim ~~45~~ 44 having an X-ray powder diffraction pattern substantially as shown in Figure 3A.

~~48.~~47. The anhydrous form A of claim ~~45~~ 44 having a differential scanning calorimetry thermogram showing an onset of an endotherm at about 191.6°C.

~~49.~~48. The anhydrous form A of claim ~~45~~ 44 having a differential scanning calorimetry

thermogram substantially as shown in figure 3B.

~~50.~~49. An anhydrous form B of the free base of N-(pentan-3-yl)-2-(3-(3-(((S)-1-((S)-tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide wherein the monohydrate form has an X-ray powder diffraction pattern comprising a characteristic peak, in terms of 2θ, at about 5.1°.

~~51.~~50. The anhydrous form B of claim ~~50~~49, wherein the X-ray powder diffraction pattern further comprises one or more characteristic peaks, in terms of 2θ, selected from peaks at about 8.5°, about 15.3°, about 17.6°, about 19.5°, and about 21.0°.

~~52.~~51. The anhydrous form A of claim ~~50~~ 49 having an X-ray powder diffraction pattern substantially as shown in Figure 4A.

~~53.~~52. The anhydrous form B of claim ~~50~~ 49 having a differential scanning calorimetry thermogram showing an onset of an endotherm at about 159.2C.

~~54.~~53. The anhydrous form B of claim ~~50~~ 49 having a differential scanning calorimetry thermogram substantially as shown in figure 4B.

~~55.~~54. An anhydrous form C of the free base of N-(pentan-3-yl)-2-(3-(3-(((S)-1-((S)-tetrahydrofuran-2-yl)ethyl)carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide wherein the monohydrate form has an X-ray powder diffraction pattern comprising a characteristic peak, in terms of 2θ, at about 5.4°.

~~56.~~55. The anhydrous form C of claim ~~55~~54, wherein the X-ray powder diffraction pattern further comprises one or more characteristic peaks, in terms of 2θ, selected from peaks at about 14.8°, about 15.1°, about 16.9°, about 18.5°, and about 19.6°.


~~57.~~56. The anhydrous form C of claim ~~55~~ 54 having an X-ray powder diffraction pattern substantially as shown in Figure 5A.

~~58.~~57. The anhydrous form C of claim ~~55~~ 54 having a differential scanning calorimetry thermogram showing an onset of an endotherm at about 166.2C.

~~59.~~58. The anhydrous form C of claim ~~55~~ 54 having a differential scanning calorimetry thermogram substantially as shown in figure 5B.

~~60.~~59. A solid form of N-(pentan-3-yl)-2-(3-(3-(((S)-1-((S)-tetrahydrofuran-2-yl)ethyl) carbamoyl)-1H-pyrazol-5-yl)phenyl)oxazole-5-carboxamide wherein the solid form has an X-ray powder diffraction pattern comprising a characteristic peak, in terms of 2θ, at about 24.6°.

~~61.~~60. The compound according to claim 1 wherein the compound of formula (I) is



.

61. A compound or a pharmaceutically acceptable salt, hydrate, or co-crystal thereof of any one of claims 1 to 17 or the pharmaceutical composition of any one of claims 18 to 24 for use in the treatment of a disease associated with impaired mucociliary clearance in a subject.